GLP-1 receptor agonists raise risk of biliary disease: review
The findings point to 'potential under-reporting' of biliary-related adverse events, researchers say
GLP-1 receptor agonists raise the risk of gall bladder and bile duct diseases, especially when prescribed at higher doses for weight loss, according to a systematic review and meta-analysis.
Although the absolute risk increase was modest, Chinese researchers say doctors and patients should still be alert to these safety signals both in clinical practice and future trials.
